Postpartum Extended-Release Buprenorphine Tissue Necrosis

BACKGROUND: Extended-release buprenorphine (XRB) may improve medication for opioid use disorder continuation among postpartum individuals. However, obstetric clinicians have relatively little experience with XRB. We describe two cases of XRB-related tissue necrosis in postpartum individuals to highl...

Full description

Saved in:
Bibliographic Details
Published inObstetrics and gynecology (New York. 1953) Vol. 142; no. 6; pp. 1504 - 1508
Main Authors Kurtz, Theresa, Charles, Jasmin E., Schwartz, Megan, Smid, Marcela C
Format Journal Article
LanguageEnglish
Published 01.12.2023
Online AccessGet full text

Cover

More Information
Summary:BACKGROUND: Extended-release buprenorphine (XRB) may improve medication for opioid use disorder continuation among postpartum individuals. However, obstetric clinicians have relatively little experience with XRB. We describe two cases of XRB-related tissue necrosis in postpartum individuals to highlight recommended injection technique and management strategies for this rare complication. CASES: One patient developed tissue necrosis after her initial injection. Her wound was expectantly managed. Another patient on long-term XRB developed tissue necrosis within 1 day of injection. General surgery excised the depot. Both instances were attributed to injection of XRB intradermally rather than subcutaneously. Both patients continued monthly XRB without recurrence, suggesting that this complication is not an allergy. CONCLUSION: Clinicians should be able to prevent, recognize, and manage tissue necrosis, a rare complication of XRB injection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0029-7844
1873-233X
DOI:10.1097/AOG.0000000000005425